临床局限性前列腺癌:AUA/ASTRO/SUO指南第一部分
该指南由AUA、ASTRO和SUO制定,基于癌症严重程度分层提供临床框架,涵盖风险分层、共同决策与治疗选择。系统评价涵盖2007年1月至2014年3月文献,并补充检索至2016年8月,证据强度分为A、B、C级以支持强、中、条件推荐。
要点
- 指南按癌症严重程度分层,辅助治疗决策与实施。
- 证据强度A(高)、B(中)、C(低)对应强、中、条件推荐。
- 选择管理策略时应考虑患者偏好。
核心结论
- 该指南旨在提高临床医生治疗局限性前列腺癌患者的能力,但未来试验需更高质量证据以改善诊疗水平。
- 在所有情况下,选择管理策略时应考虑患者偏好。
研究设计与样本
- 由AUA、ASTRO和SUO制定的基于证据的指南,采用按癌症严重程度分层的临床框架。
- 系统评价由美国医疗保健研究与质量局完成,并经ECRI研究所补充,纳入2007年1月至2014年3月发表的文献,更新检索至2016年8月。
主要发现
- 指南提供了按癌症严重程度分层的风险分层和治疗选择框架。
关键数值与推荐
- 证据强度分为A(高)、B(中)、C(低),分别支持强推荐、中等推荐、条件推荐。
- 额外信息以临床原则和专家意见形式提供。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This guideline is structured to provide a clinical framework stratified by cancer severity to facilitate care decisions and guide the specifics of implementing the selected management options. The summary presented represents Part I of the two-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline discussing risk stratification and care options by cancer severity. MATERIALS AND METHODS: The systematic review utilized in the creation of this guideline was completed by the Agency for Healthcare Research and Quality and through additional supplementation by ECRI Institute. This review included articles published between January 2007 and March 2014 with an update search conducted through August 2016. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. Additional information is provided as Clinical Principles and Expert Opinions (table 2 in supplementary unabridged guideline, http://jurology.com/). RESULTS: The AUA (American Urological Association), ASTRO, and SUO (Society of Urologic Oncology) formulated an evidence-based guideline based on a risk stratified clinical framework for the management of localized prostate cancer. CONCLUSIONS: This guideline attempts to improve a clinician's ability to treat patients diagnosed with localized prostate cancer, but higher quality evidence in future trials will be essential to improve the level of care for these patients. In all cases, patient preferences should be considered when choosing a management strategy.
引用
- Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2017. PMID: 29203269. doi:10.1016/j.juro.2017.11.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。